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Abstract: Background: Recent scientific reports on the use of high dose tigecycline monotherapy
as a “drug of last resort” warrant further research into the use of this regimen for the treatment of
severe multidrug-resistant, Gram-negative bacterial infections. In the current study, the therapeutic
efficacy of tigecycline monotherapy was investigated and compared to meropenem monotherapy in a
newly developed rat model of fatal lobar pneumonia–septicemia. Methods: A Klebsiella pneumoniae
producing extended-spectrum β-lactamase (ESBL) and an isogenic variant producing K. pneumoniae
carbapenemase (KPC) were used in the study. Both strains were tested for their in vitro antibiotic
susceptibility and used to induce pneumonia–septicemia in rats, which was characterized using
disease progression parameters. Therapy with tigecycline or meropenem was initiated at the moment
that rats suffered from progressive infection and was administered 12-hourly over 10 days. The
pharmacokinetics of meropenem were determined in infected rats. Results: In rats with ESBL
pneumonia–septicemia, the minimum dosage of meropenem achieving survival of all rats was
25 mg/kg/day. However, in rats with KPC pneumonia–septicemia, this meropenem dosage was
unsuccessful. In contrast, all rats with KPC pneumonia–septicemia were successfully cured by
administration of high-dose tigecycline monotherapy of 25 mg/kg/day (i.e., the minimum tigecycline
dosage achieving 100% survival of rats with ESBL pneumonia–septicemia in a previous study).
Conclusions: The current study supports recent literature recommending high-dose tigecycline as a
last resort regimen for the treatment of severe multidrug-resistant bacterial infections. The use of
ESBL- and KPC-producing K. pneumoniae strains in the current rat model of pneumonia–septicemia
enables further investigation, helping provide supporting data for follow-up clinical trials in patients
suffering from severe multidrug-resistant bacterial respiratory infections.
Keywords: tigecycline; meropenem; pneumonia; septicemia; Klebsiella pneumoniae; antibiotic resistance
1. Introduction
Recent data from the U.S. indicate that Gram-negative bacteria are responsible for more than
30% of hospital-acquired infections [1]. A complicating factor in the treatment of infections caused
by Gram-negative bacteria is the worldwide increase of antimicrobial resistance. In particular,
Gram-negative bacteria resistant to carbapenem antibiotics—due to the presence of plasmid-mediated
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multidrug resistance, such as with extended-spectrum β-lactamase (ESBL) or Klebsiella pneumoniae
carbapenemase (KPC)—can no longer be effectively treated with β-lactam antibiotics and tend to be
susceptible only to “drugs of last resort” [2,3].
Tigecycline (an antibiotic belonging to the class of glycylcyclines) is one such drug of last resort,
although resistance to tigecycline has been reported [4]. Further, although the United States Food and
Drug Administration (FDA) issued a warning in 2013 relating to an apparent increased death rate
during antibiotic treatment using tigecycline (loading dose of 100 mg followed by 50 mg every 12
h) [5], multiple studies have suggested that using a high dose of tigecycline could actually improve
the outcome in comparison to conventional dosing [6,7]. Additionally, the European Committee on
Antimicrobial Susceptibility Testing (EUCAST) has recently recommended the use of high-dosage
tigecycline treatment in seriously ill patients infected with multidrug-resistant bacteria [8]. As well
as dosing issues, another debate about the role of tigecycline involves its use in monotherapy as
opposed to combination therapy, particularly in the treatment of multidrug-resistant, Gram-negative
bacterial infections. This issue is complicated by the fact that comparative clinical efficacy studies into
tigecycline are complex, involving differing patient characteristics, various combinations of antibiotics,
and differences in the nature and severity of infections [9,10].
To investigate this issue further, in rats we developed a model of bilateral pneumonia–septicemia,
in which we were able to compare the therapeutic efficacy of individual antibiotics at similar conditions
of severity, duration of infection, and host defense. This novel pneumonia–septicemia model was
based on a previously established rat model of unilateral pneumonia–septicemia (in which one lung
was left uninfected), which was intended for antimicrobial pharmacokinetic and pharmacodynamic
studies [11]. Further, in order to mimic the actual clinical situation, the rat infection model is fatal if
left untreated, with rat survival (based on rats reaching humane endpoints) as a treatment outcome
parameter. In the present study, we established and characterized the lobar pneumonia leading to
fatal septicemia, which was caused by either an ESBL-positive K. pneumoniae strain or its isogenic
KPC-positive variant. The model was used to investigate the therapeutic efficacy of tigecycline as
monotherapy as compared to meropenem monotherapy, a potent carbapenem antibiotic that serves as
the conventional treatment for multidrug-resistant, Gram-negative bacterial infections [12].
2. Materials and Methods
2.1. Bacterial Strains
K. pneumoniae American Type Culture Collection (ATCC) 43816™ (capsular serotype 2) was used
as a parent strain to generate the isogenic ESBL-producing variant K. pneumoniae ESBL EMC2003
(referred to in this study as K. pneumoniae ESBL) and the isogenic KPC-producing variant K. pneumoniae
KPC EMC2014 (referred to in this study as K. pneumoniae KPC) via bacterial conjugation with an
ESBL-producing or KPC-producing clinical isolate and subsequent selection on antibiotic agar plates.
The stability of both plasmid-containing strains was assessed through five consecutive passages
in Mueller–Hinton II broth (Becton Dickinson BV, Vianen, The Netherlands). The virulence of the
bacterial strains was maintained by rat lung passage every 12 months. ATCC Quality Control strains
K. pneumoniae ATCC 13883™ (WT), K. pneumoniae ATCC 700603™ (ESBL), and K. pneumoniae ATCC
BAA1705™ (KPC) were used as reference strains.
2.2. Genotypic Characterization of Bacterial Strains
Due to the complex relationship between antibiotic resistance and virulence factors, it is important
to report the genotypic data of bacterial strains used in microbiological studies [13,14]. Polymerase chain
reaction (PCR) assays were used to verify the presence of the following resistance genes: cefotaxime
(CTX)-M β-lactamase groups 1, 2, 8, 9, 25 [15]; temoniera (TEM) β-lactamase [16]; sulfhydryl reagent
variable (SHV) β-lactamase [17]; oxacillinase (OXA) 1-like β-lactamase groups 1, 48 [18,19]; KPC [20];
and New Delhi metallo-β-lactamase 1 (NDM) [21]. Multilocus sequence typing (MLST) was used to
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investigate genetic relatedness. For this, partial DNA sequences of the seven housekeeping genes gapA,
infB, mdh, pgi, phoE, rpoB, and tonB were generated and compared using a published high-throughput
MLST (HiMLST) strategy [22] that had been adapted for K. pneumoniae isolates [23]. To further assess
the genetic relation between the strains, pulsed-field gel electrophoresis (PFGE) was used as previously
described [24].
2.3. Antibiotics and Anesthetics
The antibiotics used were amikacin hydrate, ceftazidime hydrate, ciprofloxacin hydrochloride
monohydrate, colistin sulfate salt, gentamicin sulfate, meropenem trihydrate, norfloxacin, tigecycline,
tobramycin sulfate salt, trimethoprim, and sulfamethoxazole (Sigma-Aldrich Chemie BV, Zwijndrecht,
the Netherlands). For co-trimoxazole, the ratio of trimethoprim/sulfamethoxazole was 1:19. Meropenem
was combined with cilastatin sodium (Bosche Scientific LLC, New Brunswick, NJ, USA) (1:1) when used
in vivo to inhibit the function of dehydropeptidase enzyme, which is a known catalyst of meropenem
in rats [25].
The anesthetics used were medetomidine hydrochloride (Eurovet Animal Health BV, Bladel, The
Netherlands), fentanyl citrate (Hameln Pharma Plus GmbH, Hameln, Germany), and midazolam
hydrochloride (Actavis Group PTC ehf, Hafnarfjörður, Iceland), which were administered together
intraperitoneally at 0.5 mg/kg, 50 µg/kg, and 5 mg/kg, respectively. Antagonists were atipamezole
hydrochloride (Vetoquinol BV’s, Hertogenbosch, the Netherlands), naloxone hydrochloride dihydrate
(Hameln Pharma Plus GmbH), and flumazenil (Fresenius Kabi Nederland BV, Zeist, The Netherlands),
which were administered together intraperitoneally at 1.5 mg/kg, 0.7 mg/kg, and 0.3 mg/kg, respectively.
2.4. Antimicrobial Susceptibility of K. pneumoniae Strains
The antimicrobial susceptibility of bacterial strains was assessed by determination of the minimum
inhibitory concentration (MIC) using the broth microdilution method following EUCAST guidelines [26],
which represents the lowest antibiotic concentration needed to inhibit bacterial growth under
standardized and predefined laboratory conditions. Phenotypic characterization of bacterial strains
was based on antimicrobial susceptibility as determined using the VITEK®2 system and AST-N344
Gram-Negative Susceptibility Cards (bioMérieux Benelux BV, Zaltbommel, The Netherlands).
2.5. Concentration- and Time-Dependent Bactericidal Activity of Antibiotics In Vitro
The bacterial killing capacity of meropenem and tigecycline was investigated using the time–kill
kinetics (TKK) assay, as previously described [27]. Two-fold increasing antibiotic concentrations were
used representing 1/16-fold up to 32-fold the epidemiological cutoff value (ECOFF) values of the two
antibiotics, as reported by EUCAST [28]. The ECOFF of K. pneumoniae for meropenem is 0.125 mg/L
and for tigecycline was 1 mg/L, but has recently been increased to 2 mg/L. Samples were centrifuged
at 12,500× g for 5 min to avoid drug carry-over, serially 10-fold diluted, and subcultured on Mueller
Hinton II agar plates (Becton Dickinson BV, Vianen, The Netherlands) for colony-forming unit (CFU)
counts after 24 h at 37 ◦C. At 24 h, changes in antibiotic susceptibility were determined via MIC assay
using subsamples of 1 mL to prepare bacterial inocula.
2.6. Animals
Specified pathogen-free (SPF) male strain RP–AEur–RijHsd albino rats bred at the Laboratory
Animals Center of Erasmus University Medical Center Rotterdam (Erasmus MC) were used. Rats
(age, 10–18 weeks; body weight, 250–350 g) were housed individually in ventilated cages and were
given food and water ad libitum. Rats were randomly allocated to experimental groups once they
reached the appropriate age and body weight. Group sizes were based on estimates of the hazard ratio.
Euthanasia was applied by CO2 exposure when humane endpoints were reached or at termination
of experiments.
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2.7. Ethics
Animals were maintained and handled in accordance with the Guidelines for Accommodation and
Care of Animals (European Convention for the Protection of Vertebrate Animals Used for Experimental
and Other Scientific Purposes). All animal procedures were performed in accordance with the Dutch
Animal Experimentation Act (BWBR0003081), which meets the requirements of the European Union
Animal Directive (2010/63/EU). Experimental procedures were approved by the Institutional Animal
Care and Use Committee of the Erasmus MC. The current study was designed to abide by the “three
Rs” principles of animal research (replace, reduce, refine) wherever possible [29] and was written to
conform to the animal research: reporting of in vivo experiments (ARRIVE) guidelines for reporting
animal research [30].
2.8. Rat Model of Pneumonia–Septicemia
Acute bilateral pneumonia–septicemia in rats (referred to in this study as ESBL
pneumonia–septicemia or KPC pneumonia–septicemia) was established in groups of 11 rats using
suspensions of washed bacteria in the logarithmic phase of growth. After intubation and cannulation
of the trachea under anesthesia, rats were held in a vertical position and the lungs were inoculated with
60 µL PBS containing the respective absolute lethal dose (LD100) inocula: 2 × 106 K. pneumoniae ESBL or
6 × 107 K. pneumoniae KPC. An implantable programmable temperature transponder (IPTT)-300 (Plexx
BV, Elst, The Netherlands) was implanted subcutaneously. Infected rats were monitored 12-hourly
for 11 days to assess the disease progression and pre-defined humane endpoints by changes in body
temperature and body weight, as well as by external symptoms of disease, including ungroomed
appearance, pallor, nose bleeding, lack of reactivity, inactivity, instability, or abnormal breathing of
rats. Rat survival was based on rats reaching humane endpoints, at which point euthanasia was
applied by CO2 exposure. After dissection, bacteria isolated from lungs and blood were identified by
matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry (Bruker
Daltonics, Bremen, Germany) to rule out co-infection, a pre-established exclusion criterium.
2.9. Characterization of Pneumonia–Septicemia Model
The early phase of infection was characterized at 24 h and 48 h after initiation of infection by viable
counts of K. pneumoniae in lungs and blood taken from 6 rats per time point. Blood obtained by cardiac
puncture was collected from euthanized rats in lithium heparin tubes (Sarstedt BV, Etten-Leur, The
Netherlands). The five lung lobes were collected separately in 2 mL PBS each and homogenized using
the gentleMACS™ Octo Dissociator (Milteny Biotec BV, Leiden, The Netherlands). Blood and lung
homogenates, either undiluted or in 10-fold dilutions, were subcultured on Mueller–Hinton II agar
plates (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) for CFU counts after 24 h at 37 ◦C. In
blood plasma samples, the alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT)
levels were assessed for hepatic function, and the creatinine and blood urea nitrogen (BUN) levels were
assessed for renal function. Histopathological examination of the infected lungs at 24 h after infection
was performed in 2 rats with ESBL pneumonia–septicemia and 2 rats with KPC pneumonia–septicemia.
In sacrificed rats, in situ lungs were fixated with 10% formalin under constant pressure to re-expand
the lungs. Segments of the left lung were dehydrated in ethanol and toluol, and finally embedded in
paraffin. Paraffin-embedded tissues were cut into 4-µm sections, from which one in every 15 cuts was
used for hematoxylin–eosin (HE) staining and one for Gram staining.
2.10. Antimicrobial Treatment of Pneumonia–Septicemia
The therapeutic response to meropenem was determined in rats with ESBL pneumonia–septicemia
and rats with KPC pneumonia–septicemia. The response to tigecycline was only investigated in
rats with KPC pneumonia–septicemia, as this had already been investigated in a previous unilateral
pneumonia–septicemia rat model caused by the identical K. pneumoniae ESBL strain [11]. Treatment
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groups consisted of 11 rats. Antibiotics were always administered intraperitoneally at a volume of
2.5 mL/kg 12-hourly for 10 days, starting at 24 h after initiation of infection. Meropenem in doses
ranging from 6.25 to 25 mg/kg/day were administered by 2-fold increases until a minimum effective
dose (MED) of meropenem was reached, at which all rats survived. Tigecycline was administered at 25
mg/kg/day (i.e., the MED necessary for survival of all rats with ESBL pneumonia–septicemia from a
previous study) [11]. Disease progression was monitored 12-hourly. Rats reaching humane endpoints
were euthanized and dissected to rule out co-infection.
2.11. Pharmacokinetics of Meropenem
Meropenem plasma concentrations were determined in 3 rats with ESBL pneumonia–septicemia.
Rats received 3 doses of 25 mg/kg/day meropenem 12-hourly, starting at 24 h after initiation of
infection. Blood obtained by tail vein puncture was collected in ethylenediaminetetraacetic acid (EDTA)
tubes (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). Meropenem concentrations were
determined by high-performance liquid chromatography-mass spectrometry (HPLC-MS) [31]. The
lower limit of quantification of meropenem was 0.20 mg/L. The calibration line was linear from 0.20
to 40.0 mg/L, with a determination coefficient of at least 0.995. Rat samples were prepared together
with calibration standards and quality control samples at three levels. The values of the volume
of distribution (V), the clearance (CL), and the concentration half-life time (t1/2) of the meropenem
elimination process were calculated using a PKSolver 2.0 one-compartment model of extravascular
administration with time delay to account for absorption [32]. The V and CL were presented as a
fraction of the absorbed dose (bioavailability, F). The protein binding of meropenem in rats has been
reported as 22.4% [33]. As only the unbound fraction of the drug is responsible for its antimicrobial
effect, the values of (1) the cumulative percentage of a 12-h period that the unbound fraction of drug
exceeded the MIC (ƒT > MIC) and (2) the highest unbound meropenem concentration reached in blood
plasma (ƒCmax), were calculated based on unbound meropenem concentrations.
2.12. Statistical Analysis
Kaplan–Meier rat survival curves were generated, and statistical differences in rat survival rates
were calculated using the log rank test using Prism 5.01 (Graphpad Inc., San Diego, CA, USA).
3. Results
3.1. Bacterial Strains
The results from HiMLST (Supplementary Table S1) and PFGE assays confirmed the isogenicity of
the K. pneumoniae ESBL and K. pneumoniae KPC strains. ESBL and KPC resistance genes were detected
via PCR, as expected in the respective strains (Supplementary Table S1).
3.2. Antimicrobial Susceptibility of K. pneumoniae Strains
The antimicrobial susceptibility of K. pneumoniae ESBL and K. pneumoniae KPC for clinically
relevant antibiotics was assessed by MIC determination and compared with the MIC values of 3 ATCC
Quality Control reference strains. The K. pneumoniae ESBL strain was resistant to ceftazidime and
tobramycin, and susceptible to meropenem based on MIC values (Table 1). The isogenic K. pneumoniae
KPC strain was resistant to ceftazidime, tobramycin, and meropenem. According to the EUCAST 2020
guidelines, both K. pneumoniae isolates are resistant to tigecycline, as are all the reference strains used
in this study [26]. However, both K. pneumoniae isolates still fell within the antimicrobial wild-type
distribution of K. pneumoniae based on the ECOFF value of tigecycline for K. pneumoniae (2 mg/L),
and can be considered representative of the tigecycline susceptibility of wild-type K. pneumoniae
populations—albeit on the high end of the wild-type distribution [28].
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Table 1. Minimum inhibitory concentration (MIC) values of clinically relevant antibiotics for K.
pneumoniae strains.
Strain ATCC43816
EMC
2003
EMC
2014
ATCC
13883
ATCC
700603
ATCC
BAA1705
Phenotype WT Parent ESBL KPC WT ESBL KPC
MIC
(mg/L)
CAZ 0.5 S 256 R 256 R 0.5 S 64 R 128 R
MEM 0.063 S 0.063 S 16 R 0.063 S 0.063 S 32 R
AMK 2 S 2 S 2 S 1 S 1 S 32 R
TOB 0.5 S ≥128 R ≥128 R 0.5 S 8 R 32 R
CIP 0.031 S 0.125 S 0.063 S 0.125 S 0.5 I ≥64 R
NOR 0.125 S 0.25 S 0.25 S 0.25 S 2 R 512 R
SXT 0.5 S 1 S 2 S 0.5 S 4 I ≥128 R
CST 0.5 S 1 S 0.5 S 2 S 1 S 0.5 S
TGC 1 R 1 R 2 R 1 R 16 R 4 R
MIC assays were performed in triplicate; median values are displayed. MIC values were interpreted as susceptible
(S), intermediate (I), or resistant (R) according to EUCAST 2020 guidelines. ATCC, American Type Culture Collection;
EMC, Erasmus University Medical Center Rotterdam; CAZ, ceftazidime; MEM, meropenem; AMK, amikacin;
TOB, tobramycin; CIP, ciprofloxacin; NOR, norfloxacin; SXT, trimethoprim/sulfamethoxazole expressed as the
trimethoprim concentration; CST, colistin; TGC, tigecycline; WT, wildtype; ESBL, extended-spectrum β-lactamase;
KPC, Klebsiella pneumoniae carbapenemase.
VITEK®2 data (Supplementary Table S2) showed that K. pneumoniae ESBL and K. pneumoniae KPC
were both resistant to a wide range of β-lactam antibiotics and aminoglycoside antibiotics.
3.3. Concentration- and Time-Dependent Bactericidal Activity of Antibiotics In Vitro
The in vitro killing capacity of meropenem and tigecycline against K. pneumoniae ESBL or K.
pneumoniae KPC over 24 h was determined using TKK assays. In the absence of antibiotics, the
bacterial populations rapidly increased within 24 h of incubation (Figure 1). Meropenem showed
time-dependent killing against K. pneumoniae ESBL. A concentration of ≥0.125 mg/L meropenem
resulted in a 100-fold reduction in bacterial numbers after 2 h and complete bacterial elimination after
24 h. With 0.03 mg/L meropenem, bacteria were initially killed, although after 24 h, bacterial re-growth
occurred up to the level of non-exposed bacterial growth after 24 h. However, this finding was not
associated with changes in susceptibility to meropenem. Concentrations of ≤0.015 mg/L meropenem
had no effect on in vitro bacterial growth. For K. pneumoniae KPC, initial killing by meropenem was
observed at concentrations ≥0.5 mg/L during the first 2 h exposure, but bacterial re-growth was
observed at all concentrations up to the level of non-exposed bacteria after 24 h.
The mode of action of tigecycline was observed to be bacteriostatic and the antibiotic was equally
effective against K. pneumoniae ESBL and K. pneumoniae KPC, indicating that the 2-fold difference in MIC
values to tigecycline for the two strains represents essential agreement in susceptibility to this antibiotic.
Inhibition of bacterial growth after 24 h of exposure was only observed above 2 mg/L tigecycline.
Concentrations below 2 mg/L resulted in growth inhibition during 4 h of exposure, but bacterial
re-growth occurred after 24 h, which was never associated with changes in bacterial susceptibility to
tigecycline. Concentrations ≤0.25 mg/L had no effect.
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By 48 h, differences in K. pneumoniae counts in the lungs in both models were minor. After 24 h, 
bacteremia was present in 4/6 (66%) rats with ESBL pneumonia–septicemia and in 4/6 (66%) rats with 
KPC pneumonia–septicemia. Changes in liver and kidney function in terms of ALAT, ASAT, 
creatinine, and BUN were not found. Histopathological examination of the infected lungs at 24 h after 
initiation of infection revealed distinctive alveolar pathology, as shown for KPC pneumonia–
septicemia (Figure A1 in Appendix A). Similar histopathological characteristics were observed in rats 
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infecting K. pneumoniae strain (p = 0.4662). In both cases, the body temperatures (Figure 3B) initially 
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Rat body weight decreased over time (Figure 3C). A control experiment revealed that the technique 
of intubation and inoculation itself did not influence body temperature or body weight. 
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3.4. Characterization of Pneumonia–Septicemia Model
Rats were inoculated with K. pneumoniae ESBL or K. pneumoniae KPC and developed acute bilateral
pneumonia with septicemia. Bacterial numbers increased rapidly in all lung lobes, with the relatively
large lobes containing the most bacteria (Figure 2). As a consequence of a higher inoculum used
to induce KPC pneumonia–septicemia, higher counts of K. pneumoniae were found at 24 h in the
lungs of rats with KPC pneumonia–septicemia compared to rats with ESBL pneumonia–septicemia.
By 48 h, differences in K. pneumoniae counts in the lungs in both models were minor. After 24 h,
bacteremia was present in 4/6 (66%) rats with ESBL pneumonia–septicemia and in 4/6 (66%) rats
with KPC pneumonia–septicemia. Changes in liver and kidney function in terms of ALAT, ASAT,
creatinine, and BUN were not found. Histopathological examination of the infected lungs at 24 h after
initiation of infection revealed distinctive alveolar pathology, as shown for KPC pneumonia–septicemia
(Figure A1 in Appendix A). Similar histopathological characteristics were observed in rats with
ESBL pneumonia–septicemia.
The disease progression over time in terms of rat survival rate (Figure 3A) was similar for either
infecting K. pneumoniae strain (p = 0.4662). In both cases, the body temperatures (Figure 3B) initially
showed some fluctuation, but decreased over time to below the lower limit (36.1 ◦C) of normal values.
Rat body weight decreased over time (Figure 3C). A control experiment revealed that the technique of
intubation and inoculation itself did not influence body temperature or body weight.
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were used for each experiment. (A) Rat survival (Kaplan–Meier curves) of rats reaching humane 
endpoints. (B) Box plots of pooled body temperatures showing the range of the data; the dashed line 
at 34 °C represents the humane endpoint. (C) Body weight loss from the onset of the infection (mean 
± SD). 
3.5. Therapeutic Efficacy of Meropenem in Rats with ESBL Pneumonia–Septicemia 
Treatment was started at 24 h after infection, when bacterial numbers in the lung had increased 
100-fold and most rats had developed early bacteremia. Increasing doses of meropenem were 
investigated, ranging from 6.25 to 25 mg/kg/day administered 12-hourly until a MED of meropenem 
was reached, at which all rats survived. Meropenem showed a dose-dependent therapeutic activity 
and effected survival of all rats at 25 mg/kg/day—the MED (Figure 4). Rat body temperatures initially 
showed some fluctuation but stabilized around normal values after 3 days, from which time onward 
normal circadian rhythm was shown. Body weight values initially decreased but remained stable 
after 3 days. The lungs of the surviving rats sacrificed at termination of the experiment were sterile.  
2. Bacterial load of K. p eumoniae in lungs and blood of rats with K. pneumo i e
pneumonia–septic mia in the early phase of infection. Bacterial load of K. pneumonia was determined
for tot l lu gs and individual lu g lobes and blood (per mL) of rats with K. pneumoniae ESBL
pneumonia–septicemia and rats with K. pneumo iae KPC pneumonia–septicemia at 24 h and 48 h after
initiation of infection. TL, total lungs; LL, left lobe; RCrL, right cranial lobe; RML, right middle lobe;
RCaL, right caudal lobe; RIL, right intermediate lobules. Groups of 6 rats per time point. Bacterial load
is expressed as log CFU (median ± range).
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3.5. Therapeutic Efficacy of Meropenem in Rats with ESBL Pneumonia–Septicemia
Tr atment was started at 24 h after infection, when bacterial numbers in the lung had increased
100-fold and most rats had developed early bacteremia. Increasing doses of meropenem were
investigated, ranging from 6.25 to 25 mg/kg/day administered 12-hourly until a MED of meropenem
was reached, at which all rats survived. Meropenem showed a dose-dependent therapeutic activity
and effected survival of all rats at 25 mg/kg/day—the MED (Figure 4). Rat body temperatures initially
showed some fluctuation but stabilized around normal values after 3 days, from which time onward
normal circadian rhythm was shown. Body weight values initially decreased but remained stable after
3 days. The lungs of the surviving rats sacrificed at termination of the experiment were sterile.
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3.6. Pharmacokinetics of Meropenem in Rats with ESBL Pneumonia–Septicemia
Meropenem plasma concentrations were deter ined to investigate the steady-state
pharmacokinetic profile of meropenem at MED in rats with ESBL pneumonia–septicemia. The plasma
concentration–time curve indicated a one-compartment deposition (Figure 5). The corresponding
estimated pharmacokinetic parameters are displayed in Table 2. The ƒT > MIC for K. pneumoniae ESBL
was 5.18 h, which was 43.17% of the twice-daily dosing interval. For K. pneumoniae KPC, the ƒCmax
(13.37 mg/L) did not reach the respective meropenem MIC (16 mg/L), resulting in a ƒT > MIC of 0 h.
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Table 2. Pharmacokinetic parameters of meropenem in rats with ESBL pneumonia–septicemia.
Pharmacokinetic
Parameter
V/F CL/F t1/2 ƒCmax
ƒT > MIC
0.063 mg/L 16 mg/L
L/kg L/kg/h h mg/L h % h %
Estimate 1.03 1.17 0.61 13.37 5.18 43.17 0.00 0.00
SEM 0.07 0.06 0.03 1.43 0.24 2.00 0.00 0.00
Plasma concentrations of meropenem in rats with ESBL pneumonia–septicemia treated 12-hourly with 3 consecutive
doses of 25 mg/kg meropenem, starting at 24 h after initiation of infection. The ƒT > MIC was calculated based
on unbound meropenem concentrations using the MIC of K. pneumoniae ESBL (0.063 mg/L) and the MIC of K.
pneumoniae KPC (16 mg/L) and is shown in hours (h) as well as percentage of the 12-h dosing interval (%). V, volume
of distribution; F, bioavailability; CL, clearance; t1/2, elimination half-life time; ƒCmax, highest unbound meropenem
concentration reached in blood plasma; ƒT > MIC, cumulative percentage of a 12-h period that the unbound fraction
of drug exceeds the MIC.
3.7. Therapeutic Efficacy of Meropenem and Tigecycline in Rats with KPC Pneumonia–Septicemia
Rats with KPC pneumonia–septicemia were treated with 25 mg/kg/day meropenem 12-hourly for
10 days, which correlates to a ƒT > MIC of 0 h. This treatment resulted in survival of only 1/12 rats
with KPC pneumonia–septicemia (Figure 6), which was not significantly different compared to the
placebo-treated rats (p = 0.5728). The failure of meropenem treatment was also reflected in the body
temperatures and the body weight values.Antibiotics 2019, 8, x FOR PEER REVIEW 11 of 18 
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Next, the therapeutic response to tigecycline treatment of 25 mg/kg/day 12-hourly for 10 days
was investigated in rats with KPC pneumonia–septicemia. This dosage was the MED of tigecycline
found in a previous unilateral pneumonia–septicemia rat model caused by an identical K. pneumoniae
ESBL strain [11]. The 25 mg/kg/day tigecycline dosage resulted in survival of all rats with bilateral
KPC pneumonia–septicemia. Body temperatures remained stable, but body weights decreased slowly
over time (Figure 6). Low bacterial numbers were present in the lungs of the surviving rats, with a
median of 2.6 × 103 K. pneumoniae and an upper limit of 1.9 × 104 K. pneumoniae. None of the isolated
bacteria showed a change in susceptibility to tigecycline.
4. Discussion
Antimicrobial resistance continues to spread worldwide and is often encountered in clinically
relevant organisms such as K. pneumoniae. This bacterial species is becoming increasingly resistant
to currently available antibiotics [3,34], with many isolates only susceptible to a limited number of
“last resort” antibiotics, such as colistin and tigecycline. However, much debate still exists on the
clinical efficacy of tigecycline in relation to the dose administered. Freire et al. in 2010 showed a
lower therapeutic response for tigecycline than imipenem (using a dosing regimen of 100 mg initially
followed by 50 mg every 12 h in a group of ventilated patients), a study often referenced as showing
the limited efficacy of tigecycline in this situation [35]. Additionally, the administration of tigecycline
treatment has been associated with an increased death rate [5], and a number of case reports have
indicated serious complications in patients as a consequence of tigecycline treatment [36–40]. On the
other hand, a meta-analysis by Falagas et al. in 2014 concluded that high-dose tigecycline regimens
may be effective for the treatment of severe bacterial infections [9], and a meta-analysis by Gong et al.
concluded that high-dose tigecycline regimens did not elevate the risk of toxic side effects [41]. Further,
pharmacokinetic and pharmacodynamic studies have indicated that higher dosages of tigecycline
can be administered to humans, resulting in improved therapeutic efficacy [6,42,43]. This has been
corroborated by more recent studies, which have shown that administration of high-dose tigecycline
regimens are tolerated and result in improved therapeutic efficacy in infected patients compared
to conventional tigecycline dosing [43–47]. Cunha et al. reported clinical efficacy using once-daily
high-dose tigecycline monotherapy in the treatment of multidrug-resistant Gram-negative bacilli and
published recommendations for high-dose regimens [7,42]. These studies are also supported by the
in vitro modeling studies of Tsala et al., suggesting that higher doses of tigecycline are required to
achieve therapeutic efficacy [48], and by a Monte Carlo simulation analysis of standard and high-dose
tigecycline against carbapenemase-producing K. pneumoniae, showing that the cumulative fractional
response rate of >90% was only achievable with the high-dose tigecycline regimen [49]. Taken together,
these studies suggest that current clinical guidelines on the antibiotic prescription of tigecycline may
need to be revised upwards in order to reach a clinically effective dose. In this respect, EUCAST has
recently published the new Guidance Document on Tigecycline Dosing by the EUCAST, recommending
the use of high-dosage tigecycline treatment in seriously ill patients infected with multidrug-resistant
bacteria [8].
Complicating this debate is the fact that tigecycline is frequently applied in the treatment
of infections caused by multidrug-resistant bacteria as part of combination therapy rather than
monotherapy [10]. Based on these limitations and on accompanying discussions relating to the
efficacy of tigecycline administration, a study was established into the efficacy of high-dose tigecycline
monotherapy using a newly established rat model of fatal acute pneumonia–septicemia caused by ESBL-
or KPC-positive K. pneumoniae with meropenem as a comparator drug. This model is representative of
a particularly severe multidrug-resistant infection in human patients [50–52] and allows for research
comparing the therapeutic efficacy of individual antibiotics at similar conditions of severity, duration
of infection, and host defense, which is not possible with most comparative clinical efficacy studies on
tigecycline treatment [9,10].
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Treatment with tigecycline at 25 mg/kg/day 12-hourly for 10 days resulted in 100% survival of
rats with KPC pneumonia–septicemia and normalization of body temperature. In our previous study
using the K. pneumoniae ESBL unilateral pneumonia–septicemia model, this tigecycline dosage was
the successful MED, generating 100% survival of rats and normalization of body temperature. In the
same study, the efficacy of tigecycline was found to be dose-dependent and was correlated to the
ratio of the area under the plasma concentration–time curve (AUC) to the MIC (AUC/MIC). The AUC
during a 24-h period (AUC0–24h) for this tigecycline dosage in rats with was similar to the AUC0–24h of
high-dose tigecycline treatments in human patients (a loading dose of 300 mg tigecycline followed by
150 mg tigecycline every 12 h) [53]. For pneumonia–septicemia caused by K. pneumoniae ESBL with a
tigecycline MIC of 1 mg/L, the AUC/MIC was 34.29 mg·h/L at a tigecycline dosage of 25 mg/kg/day,
which was the MED of tigecycline for survival of all rats. As the tigecycline MIC of K. pneumoniae KPC
is 2 mg/L, the extrapolated AUC/MIC ratio for KPC pneumonia–septicemia at a tigecycline dosage of
25 mg/kg/day is calculated to be 17.15 mg·h/L. Despite this MED having a lower AUC/MIC ratio in
rats with bilateral KPC pneumonia–septicemia, the tigecycline treatment at 25 mg/kg/day 12-hourly
for 10 days remained successful. Unlike the meropenem treatment, this treatment did not result in
normalization of body weight, which might be explained by either the persistence of low bacterial
numbers in the lungs of the rats at the end of treatment or by potential gastro-intestinal side effects
of tigecycline.
Treatment with meropenem in rats with ESBL pneumonia–septicemia showed a clear
dose–response relationship. At the MED of 25 mg/kg/day, meropenem resulted in 100% rat survival,
stabilization of body weight, body temperature returning to the circadian rhythm, and effected bacterial
elimination from the lung tissue at the end of treatment. Meropenem concentrations in rat plasma
remained above the MIC ofK. pneumoniae ESBL for >5 h, achieving the bactericidal target of carbapenem
regimens in human patients, which is a ƒT > MIC of approximately 40% of the dosing interval [54]. In
terms of total dosage, meropenem at 25 mg/kg/day 12-hourly for 10 days in rats is similar to the current
clinical treatment of ESBL pneumonia–septicemia, although in patients, an 8-hourly meropenem
schedule is more common [55].
The MED of meropenem in rats with ESBL pneumonia–septicemia was not successful in rats with
KPC pneumonia–septicemia, which is in line with the difference in susceptibility of K. pneumoniae
ESBL and K. pneumoniae KPC. This difference in susceptibility resulted in different ƒT > MIC values for
the two strains, with unbound meropenem concentrations in rat plasma remaining above the MIC
of K. pneumoniae ESBL for >5 h, whereas the ƒCmax (<14 mg/L) did not reach the meropenem MIC of
K. pneumoniae KPC (16 mg/L), resulting in a ƒT > MIC of 0 h. The respective therapeutic success or
failure of this meropenem dose in both infection models can be explained as a consequence of the
time-dependent bactericidal activity of meropenem, which was shown in the in vitro TKK data in the
present study, as well as in other in vivo pharmacokinetic and pharmacodynamic studies [56].
The pneumonia–septicemia model established in the present study is representative of a
particularly severe human infection with K. pneumoniae bacteria, resulting in rapid mortality when
left untreated [50–52]. Further, although the tigecycline MIC of K. pneumoniae ESBL (1 mg/L) and K.
pneumoniae KPC (2 mg/L) are considered resistant, these MICs remain within the wild-type distribution
of tigecycline MICs for K. pneumoniae [26,28]. In view of these factors, the successful treatment of this
animal model necessitated the use of a high-dose tigecycline regimen, as the AUC of the tigecycline
monotherapy MED administered to rats with ESBL pneumonia–septicemia exceeds the AUC of the
tigecycline dosage that is conventionally administered to infected patients (50 mg tigecycline every
12 h) [57], demonstrating the effectiveness of high-dosage tigecycline regimens in the treatment of
severe multidrug-resistant bacterial infections. The scope of the current research was limited to
investigating the efficacy of a high-dosage tigecycline regimen in a model of pneumonia–septicemia
caused by two isogenic, multidrug-resistant K. pneumoniae strains. Future research can improve on the
generalizability of these results by investigating high-dosage tigecycline regimens in the treatment of
infection models caused by other K. pneumoniae strains or different Gram-negative bacterial species.
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Another interesting avenue for further research with the current pneumonia–septicemia model would
be the investigation of high-dose meropenem regimens [58] or high-dose meropenem and high-dose
tigecycline combination regimens [59].
5. Conclusions
The data obtained in the current study provide evidence that high-dosage tigecycline monotherapy
is effective in a rat model representative of human pneumonia–septicemia caused by multidrug-resistant
K. pneumoniae. Based on the therapeutic tigecycline dose observed in this publication, the limited
susceptibility to tigecycline of both strains, and current clinical guidelines, the in vivo data reported
in the present study further supports recent literature on the applicability of high-dosage tigecycline
as a treatment of “last resort” in patients for severe multidrug-resistant K. pneumoniae infections.
The present work involves a clinically relevant animal model for multidrug-resistant K. pneumoniae
infections that facilitates the future investigation of antibiotics and novel therapeutic approaches
to pneumonia–septicemia.
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Figure A1. Representative lung histopathology in lung tissue from rats with K. pneumoniae KPC 
pneumonia–septicemia at 24 h after initiation of infection. (A–C) Sections stained with hematoxylin-
eosin at different magnifications. (D) Section stained with Gram stain. An outer hemorrhagic zone of 
the lesion was observed (in areas next to uninfected tissue), in which the alveoli were filled with 
mucoid exudates dominated by edema fluid and a light cellular infiltrate. More extensive areas of 
pneumonia were observed towards the center of the lesion (i.e., in the zone of early consolidation). In 
these areas, alveoli were packed with predominantly polymorphonuclear leukocytes and alveolar 
walls were necrotic. Numerous encapsulated Gram-negative bacilli were freely present in the 
exudates within the hemorrhagic zone of the lesions. 
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